Skip to content
Menu

Zeev Bovan

688 posts

Posts (688)

Zeev Bovan NBIS 3 months ago #141

$NBIS retail investors will get crazy from this stock, wait till it go down to the strong support, don’t rush to buy during pumps, they are playing with you.

$ORCL a safer place to put the money.

Zeev Bovan TARA 3 months ago #144

Overreaction, it was never about a quarterly report, it’s about the soon to be approved cancer treatment drug that will make this company profitable and send the stock price up.

$TARA

Zeev Bovan ORCL 3 months ago #145

$ORCL screen shot this post, 1000$ in 3 years, it will increase further steadily once the investments start to print money.

Zeev Bovan TARA 3 months ago #147

Scenario 1: TARA-002 becomes a best-in-class NMIBC therapy
This is the dream outcome.
Recent data showed:
72% complete response rate at any time
67% complete response at 6 months
55% complete response at 12 months in the BCG-naïve NMIBC cohort
Favorable safety profile with no Grade 3+ treatment-related adverse events reported in that update
If future registrational trials confirm strong efficacy, investors may value TARA as a future oncology commercial company rather than a speculative biotech.
Possible valuation:
Assume:
Market Cap Approximate Stock Price*
$500M ~$9
$1B ~$18
$2B ~$36
*Approximate based on ~56M shares outstanding; actual dilution could change this.
A $1B–$2B valuation is not impossible for a biotech with a successful cancer drug, but it requires major clinical and regulatory wins.
🚀 Catalysts That Could Send TARA Higher

  1. ADVANCED-3 registrational trial
    This is probably the biggest catalyst.
    The company has said it plans to initiate the ADVANCED-3 registrational trial in BCG-naïve NMIBC patients in the second half of 2026.
    A strong trial design + FDA alignment could trigger institutional buying.
    Potential impact: Very High ⭐⭐⭐⭐⭐
  2. FDA acceleration
    TARA already received Breakthrough Therapy and Fast Track designations for TARA-002 in lymphatic malformations.
    More FDA support for bladder cancer could dramatically change investor perception.
    Potential impact: Very High ⭐⭐⭐⭐⭐
  3. Partnership / buyout speculation
    Large oncology companies often acquire small biotech firms after promising Phase 2/3 data.
    A partnership could:
    validate TARA-002
    bring upfront cash
    reduce financing risk
    Potential impact: Extremely High ⭐⭐⭐⭐⭐
  4. Short squeeze / momentum
    Because TARA is a small biotech, positive news could create outsized moves if liquidity is limited.
    This is a trading catalyst, not a fundamental one.
    Potential impact: Medium-High ⭐⭐⭐⭐
Zeev Bovan SNDK 3 months ago #149

2 weeks this ballon goes back to where it was, dragging all the market with it, that bs pumping has to be regulated and stopped.

Zeev Bovan PLTR 3 months ago #150

PE of 150? you are giving a cash advance as if Palantir is skynet dominating the world and literally sending terminators back in time, it’s ridicules for people like Buffet who saw great companies with an extraordinary stock price crash and unfortunately for the bulls this is what makes stocks moving, the big money, not the small retail investors.